Fermenta Biotech will hold a meeting of the Board of Directors of the Company on 10 December 2025.Powered by Capital Market - Live News

Net profit of Fermenta Biotech rose 65.91% to Rs 18.88 crore in the quarter ended September 2025 as against Rs 11.38 crore during the previous quarter ended September 2024. Sales rose 37.03% to Rs 130.22 crore in the quarter ended September 2025 as against Rs 95.03 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales130.2295.03 37 OPM %20.4619.76 - PBDT29.4917.97 64 PBT24.0811.82 104 NP18.8811.38 66 Powered by Capital Market - Live News

Fermenta Biotech will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live News

Fermenta Biotech announced that the Indian Patent Office has formally granted a patent for its invention of a plant-based Vitamin D3. Fermenta`s newly granted patent safeguards its proprietary process for producing plant based Vitamin D3, marking a significant advancement in its innovation pipeline and reinforcing its leadership in the global Vitamin D3 domain. This market-leading vegan solution responds to the accelerating global demand for ethically sourced, sustainable nutrition and positions Fermenta at the forefront of the plant-based nutrition revolution. By enabling the production of completely vegan and vegetarian-friendly Vitamin D3, the invention captures emerging opportunities across nutraceutical and food fortification sectors, where sustainable, plant-derived ingredients command premiums and growing market share. Prashant Nagre, Managing Director of Fermenta, said: �The grant of this patent is a proud milestone in our journey of innovation. It reflects our dedication to addressing evolving consumer needs with environmentally conscious solutions. Plant-based Vitamin D3 represents the future of nutrition, and this patent reinforces our ability to deliver differentiated offerings that create long-lasting impact for both our partners and society at large. It also strengthens India`s role as a hub for pioneering industrial innovation, showcasing how local science can contribute to global wellness.� Powered by Capital Market - Live News

Net profit of Fermenta Biotech reported to Rs 21.83 crore in the quarter ended June 2025 as against net loss of Rs 5.82 crore during the previous quarter ended June 2024. Sales rose 74.40% to Rs 136.26 crore in the quarter ended June 2025 as against Rs 78.13 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales136.2678.13 74 OPM %20.721.02 - PBDT33.900.19 17742 PBT28.09-5.93 LP NP21.83-5.82 LP Powered by Capital Market - Live News